Pfizer (United States)

A Head-to-Head Comparison of Three Literature Algorithms for Physical Activity Endpoints from a Wrist Accelerometer in Free-Living Conditions

Wrist accelerometers are widely used in clinical trials for continuous assessment of participants’ day-to-day physical activity and function, through derivation of metrics such as time spent in sedentary, non-sedentary, light, and moderate-to-vigorous physical activity (MVPA). Mu...

Photoproximity labeling of c-Myc reveals SLK as a cancer-specific co-regulator

Transcription factors (TFs) have long been aspirational therapeutic targets for the treatment of diseases, as their dysregulation is a common mechanism for altered cell states. Despite this, many TFs implicated in disease have disordered structures and lack canonical binding pock...

Condition-Specific LC Retention Time Prediction: Feature-Selected QSRR Versus Pretrained Graph Isomorphism Network Transfer Learning

Condition-specific liquid chromatographic retention time prediction remains challenging because retention depends on both molecular structure and experimental conditions. This study compared feature-selected quantitative structure–retention relationship (FS-QSRR) models with pret...

How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data

BACKGROUND: Multiple phase 3 metastatic castration-sensitive prostate cancer (mCSPC) studies consistently show a prostate-specific antigen (PSA) nadir of <0.2 ng/mL to be the preferred threshold for PSA response. However, in real-world practice, physicians often use other metrics...

Predicting SolvateFormation in Complex MulticomponentSolvent Mixtures from Binary Measurements and Thermodynamics Modeling

Abstract Mapping crystallization outcomes in ternary solvent mixtures for systems able to solvate remains experimentally intensive due to the significant compositional phase space that needs to be explored to derive complete phase diagrams. Here, we show that these phase diagrams...

Phase 3 Randomized Study Investigating the Safety, Tolerability, and Immunogenicity of a Combination Modified Messenger RNA Vaccine Against Influenza and COVID-19 in Healthy Adults

Background/Objectives: Vaccination remains an important means of protection against influenza and COVID-19. Administering influenza and COVID-19 vaccines as a combined formulation may be advantageous. Methods: This phase 3, randomized study evaluated an investigational combinatio...

A second yearly booster dose of the VLA15 Lyme borreliosis vaccine candidate in healthy individuals

Human vaccines against Lyme borreliosis, the most common tick-borne illness in Northern Hemispheric temperate climates, remain unavailable. Previous evaluations demonstrated the safety and immunogenicity of primary and booster dosing with VLA15, an investigational vaccine contain...

Effect of Abrocitinib on the Skin Microbiome in Patients With Moderate‐to‐Severe Atopic Dermatitis

BACKGROUND: Atopic dermatitis (AD) is characterized by microbial dysbiosis, notably an overabundance of Staphylococcus species. This study aimed to evaluate the effects of abrocitinib, a Janus kinase 1-selective inhibitor, on the skin microbiome and clinical outcomes in patients...

Long-term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase 2 Results from Double-blind and Open-Label Extension Studies

Objective To evaluate long-term safety and efficacy of dazukibart, a novel anti-interferon beta monoclonal antibody, in adults with moderate-to-severe dermatomyositis (DM). Methods Participants from two cohorts of DM (skin-predominant, SP and muscle-predominant, MP), completing a...

Modeling the public health impact of vaccination with Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025–2026 formula in the pediatric population aged 5–17 years at high risk of severe outcomes from COVID-19 in the United States

INTRODUCTION: This study evaluated the potential public health impact of receiving Pfizer-BioNTech COVID-19 vaccine, LP.8.1, 2025-2026 formula, in the US pediatric population aged 5-17 years at high risk of severe outcomes from COVID-19. RESEARCH DESIGN AND METHODS: A previously...